Verrica Pharmaceuticals Inc. reported its financial results for the quarter ended March 31, 2025, revealing a net loss of $9.7 million, or $0.10 per share. This represents a significant improvement compared to the net loss of $20.3 million, or $0.44 per share, reported in the same period in 2024. On a non-GAAP basis, the net loss was $7.8 million, or $0.08 per share, compared to a non-GAAP net loss of $17.8 million, or $0.38 per share, in the prior year. As of March 31, 2025, the company had $29.6 million in cash and cash equivalents. In terms of business developments, Verrica is advancing its clinical-stage pipeline, working in collaboration with Torii Pharmaceutical to initiate a global Phase 3 program for YCANTH, a treatment for common warts. Additionally, Verrica is progressing with its novel oncolytic peptide, VP-315, following promising Phase 2 trial results for the treatment of basal cell carcinoma. The company recently held an end-of-Phase 2 meeting with the FDA to help design a Phase 3 program.